reason report
management meet reiter confid strength
franchis pt
bottom line recent host ceo bonni anderson vice-president
ir angi mccabe number investor meet came
away view remain attract diagnost stori
three classifi test reduc diagnost uncertainti
patient potenti biopharma collabor driven upsid
given biorepositori price target move
steadi focus approach drive penetr
market creat stabl long-term strong dx franchis
revenu three test potenti biopharma upsid
three commerci test market afirma
genom classifi alreadi deliv test emerg
standard care indetermin thyroid cancer biopsi recent
improv percepta gsc genom sequenc classifi lung
cancer classifi inconclus nodul remain key growth driver
year remain focus drive steadi market
adopt three assay process gener multi-year
lead sticki market adopt hard unseat expect
medicar reimburs percepta envisia
genom classifi ipf idiopath pulmonari fibrosi expect
reimburs toward higher end rang given
multi-year effort behind afirma product posit
percepta envisia well-train sale forc like see
test continu ramp ahead
biopharma continu present upsid
biorepositori deliv valu collabor recal
establish biopharma collabor loxo
op loxo util thyroid cancer biorepositori
multi-year collabor explor use nasal
swab field injuri technolog screen lung cancer thyroid
lung cancer biorepositori contain imag truth sampl rna
transcriptom data collect real-world patient sampl make
highli valu cost effect vs gener mutat profil
de-novo high cost genom profil assay believ give
leg compet dx compani thyroid
lung cancer biopharma partnership collabor expect
deliv beyond project expand nasal
swab data expect believ three classifi
test remain core success longer term potenti upsid
profit sight busi model start deliv
expect cash flow break-even year track deliv
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
profit next year excel cost manag recent
promot cfo keith kennedi well disciplin
invest busi deliv much improv oper
profil vs prior year believ continu improv
gain adopt percepta envisia sale forc
fulli train three test help drive leverag across
franchis recent capit rais pay
debt consider flexibl inorgan growth well
ceo anderson caution like remain disciplin
pursu asset fit indic focu oper profil
rate share outperform price target
address company-estim diagnost market via neg classifi test help
reduc ambigu diagnosi sizabl subset thyroid lung cancer patient well
dramat reduc unnecessari surgeri vcyt test improv diagnosi save
healthcar cost believ pose signific valu provid payer
value-driven healthcar landscap develop proprietari express test
afirma identifi benign thyroid nodul indetermin tradit cytolog help
physician patient confid forgo unnecessari thyroid surgeri afirma believ
path becom standard care given thyroid fna
fine needl aspir found indetermin year suitabl test
afirma alreadi driven near penetr market compani expect
reach longer term company-estim market market
veracyt second test percepta bronchial gene express classifi
neg predict valu help identifi patient consid low risk initi
bronchoscopi result found inconclus help reduc unnecessari surgeri
save overal cost system percepta bronchial classifi address
bronchoscopi everi year lung nodul reveal ct inconclus
case drive market opportun percepta test
annual market reimburs medicar continu garner
also commerci envisia third test neg classifi test idiopath
pulmonari fibrosi ipf drive total address market three diagnost test
believ reimburs continu import driver revenu
beyond test volum compani continu build stronger payer base time
gain increasingli cover contract live drive adopt test
vcyt multi-year collabor innov earli stage discoveri therapeut arm
global lung cancer initi develop non-invas nasal swab diagnost
test lung cancer valid potenti field injuri approach posit
part collabor receiv payment addit
follow futur clinic studi grow expect gain view potenti
test present data beyond
multipl shot goal prove technolog model address
inconclus biopsi longer term believ adopt vcyt gene express
test cancer thyroid nodul lung bronchi continu increas
data reimburs updat pipelin offer addit catalyst addit believ
vcyt manag team includ ceo bonni anderson proven execut
ramp maxim revenu shift reimburs landscap
share current trade ev/sal diagnost peer
qtnt gh ghdx ttoo multipl averag given higher rate
reimburs afirma becom standard care market newli launch
test includ percepta envisia gain traction back strong clinic data
biopharma revenu ramp believ share could trade least ev/sal
estim result pt
primari risk price target includ limit reimburs
rate decis move forward visibl test includ percepta envisia fda
regul financ commit given neg cash flow near term
declin reimburs could sever impact revenu major risk
reimburs rate could decreas dramat current reimburs rate
among highest industri much revenu base
reimburs rate impact amount test administ adopt rate
exist new test vcyt ramp would sever impact refil reject
even wors reimburs rate continu fall given still early-stag compani
visibl still somewhat limit despit encourag sign still early-stag
compani neg net incom provid progress report afirma
encourag result test gain traction howev still plenti uncertainti
busi given model still show neg earn least busi
develop forecast expect face challeng new compani face
competit disadvantag limit visibl
fda regul remain risk regulatori concern fda decis
impact product still earli stage ramp envisia
could impact fda given nascent natur test fda regul could impact
product number product offer compani increas regul
fda would requir addit sg expens satisfi complianc increas cost
could also affect abil ramp
addit financ could still happen posit cash flow come later expect
possibl may need addit financ given expect neg net incom
near term expect posit cash flow come later expect compani
need anoth round financ exist debt could lead addit interest expens
increas net debt balanc sheet could also lead increas capit cost
servic
interest expens incom net
sg sale
 sale
oper expens sale
compani report svb leerink estim
